104 related articles for article (PubMed ID: 18018573)
1. [Effects of thyrotropin-suppressive therapy in patients with well-differentiated thyroid carcinoma].
Miyakawa M
Nihon Rinsho; 2007 Nov; 65(11):2073-7. PubMed ID: 18018573
[TBL] [Abstract][Full Text] [Related]
2. [Treatment with L-thyroxine for differentiated thyroid carcinoma].
Łacka K
Wiad Lek; 2001; 54 Suppl 1():368-72. PubMed ID: 12182051
[TBL] [Abstract][Full Text] [Related]
3. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer.
Biondi B; Cooper DS
Thyroid; 2010 Feb; 20(2):135-46. PubMed ID: 20151821
[TBL] [Abstract][Full Text] [Related]
4. Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy.
Taillard V; Sardinoux M; Oudot C; Fesler P; Rugale C; Raingeard I; Renard E; Ribstein J; du Cailar G
Clin Endocrinol (Oxf); 2011 Nov; 75(5):709-14. PubMed ID: 21645022
[TBL] [Abstract][Full Text] [Related]
5. Glucose tolerance and lipid profile in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomised controlled trial.
Heemstra KA; Smit JW; Eustatia-Rutten CF; Heijboer AC; Frölich M; Romijn JA; Corssmit EP
Clin Endocrinol (Oxf); 2006 Dec; 65(6):737-44. PubMed ID: 17121524
[TBL] [Abstract][Full Text] [Related]
6. Bone loss in premenopausal women on long-term suppressive therapy with thyroid hormone.
Sijanovic S; Karner I
Medscape Womens Health; 2001 Oct; 6(5):3. PubMed ID: 11698925
[TBL] [Abstract][Full Text] [Related]
7. [Hormonal replacement therapy in women after surgery for thyroid cancer treated with suppressive doses of L-thyroxine].
Jastrzebska H; Gietka-Czernel M; Zgliczyński S
Wiad Lek; 2001; 54 Suppl 1():383-8. PubMed ID: 12182054
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in longterm exogenous subclinical hyperthyroidism and the effects of restoration of euthyroidism, a randomized controlled trial.
Eustatia-Rutten CF; Corssmit EP; Pereira AM; Frölich M; Bax JJ; Romijn JA; Smit JW
Clin Endocrinol (Oxf); 2006 Mar; 64(3):284-91. PubMed ID: 16487438
[TBL] [Abstract][Full Text] [Related]
9. Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer.
Do Cao C; Wémeau JL
Ann Endocrinol (Paris); 2015 Feb; 76(1 Suppl 1):1S47-52. PubMed ID: 26826483
[TBL] [Abstract][Full Text] [Related]
10. Follow-up of differentiated thyroid carcinoma.
Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
[TBL] [Abstract][Full Text] [Related]
11. Cognitive functions and mood during chronic thyrotropin-suppressive therapy with L-thyroxine in patients with differentiated thyroid carcinoma.
Jaracz J; Kucharska A; Rajewska-Rager A; Lacka K
J Endocrinol Invest; 2012 Sep; 35(8):760-5. PubMed ID: 21986400
[TBL] [Abstract][Full Text] [Related]
12. Thyroid-hormone therapy and thyroid cancer: a reassessment.
Biondi B; Filetti S; Schlumberger M
Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):32-40. PubMed ID: 16929364
[TBL] [Abstract][Full Text] [Related]
13. [Hormone replacement in patients with carcinoma of the thyroid (author's transl)].
Creutzig H; Kallfelz I; Haindl H; Schulle R; Hundeshagen H
Dtsch Med Wochenschr; 1977 Dec; 102(48):1763-6. PubMed ID: 411647
[TBL] [Abstract][Full Text] [Related]
14. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
15. The role of thyrotropin suppression in patients with differentiated thyroid carcinoma.
Deasy J; Prichard RS; Evoy D; McDermott EW
Ir Med J; 2010; 103(7):202-5. PubMed ID: 20845598
[TBL] [Abstract][Full Text] [Related]
16. [Effects of chronic subclinical hyperthyroidism from levothyroxine on cardiac morphology and function].
Biondi B; Fazio S; Palmieri EA; Tremalaterra R; Angellotti G; Bonè F; Riccio G; Cittadini A; Lombardi G; Saccà L
Cardiologia; 1999 May; 44(5):443-9. PubMed ID: 10389349
[TBL] [Abstract][Full Text] [Related]
17. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
18. The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma.
Heemstra KA; Hamdy NA; Romijn JA; Smit JW
Thyroid; 2006 Jun; 16(6):583-91. PubMed ID: 16839260
[TBL] [Abstract][Full Text] [Related]
19. Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-t4 therapy.
Gazdag A; Nagy EV; Burman KD; Paragh G; Jenei Z
Exp Clin Endocrinol Diabetes; 2010 Jun; 118(6):381-7. PubMed ID: 19658059
[TBL] [Abstract][Full Text] [Related]
20. Body Composition, Resting Energy Expenditure, and Metabolic Changes in Women Diagnosed with Differentiated Thyroid Carcinoma.
Izkhakov E; Vaisman N; Barnes S; Barchana M; Stern N; Keinan-Boker L
Thyroid; 2019 Aug; 29(8):1044-1051. PubMed ID: 31088334
[No Abstract] [Full Text] [Related]
[Next] [New Search]
